Use the regional gross margin data to refine revenue mix assumptions in models; monitor Sonrotoclax R&D spend as a percentage of total as a proxy for pipeline prioritization. This filing confirms previously reported U.S. GAAP results and adds transparency on geographic profitability.
Price Chart
Executive Summary
BeOne Medicines filed an 8-K to disclose additional financial information prepared under PRC GAAP in its STAR Annual Report, including gross margin by region, R&D expense allocation, and production/sales data. This filing supplements but does not replace its prior U.S. GAAP financial reporting from its February 26, 2026 earnings release.
Key Financial Metrics
Key Facts
- Filing supplements prior U.S. GAAP reporting with PRC GAAP financial data for the year ended December 31, 2025
- Discloses gross profit margin by region: 66.6% in China and 97.0% ex-China for 2025
- Provides R&D expense allocation by product, showing $176.7M spent on Sonrotoclax in 2025
- Reveals 2025 production of 6.27M vials, sales of 5.99M vials, and ending inventory of 2.91M vials for key products
- Highlights key differences between U.S. GAAP and PRC GAAP accounting policies for share-based compensation, leasing, and royalty transfers
Financial Impact
No material change to previously reported U.S. GAAP financials; provides supplemental regional margin and R&D detail
Risk Factors
- Accounting differences between U.S. GAAP and PRC GAAP could lead to investor confusion if not properly reconciled
- Higher R&D spend on newer assets like Sonrotoclax may pressure near-term margins if commercialization timelines slip
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001651308-26-000008 |
| Document: bgne-20260414.htm | 0001651308-26-000008 |
| Document: 0001651308-26-000008-index-headers.html | 0001651308-26-000008 |
| Document: 0001651308-26-000008-index.html | 0001651308-26-000008 |
| Document: 0001651308-26-000008.txt | 0001651308-26-000008 |
| 8-K Data (Synthetic) | 0001651308-26-000008 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 8, 2026 20w ago | 144 | $21.95 $21.95 | · 0.00% | ▼ −4.08% | $21.95 (−0.00%) |
May 6, 2026 24w ago | 8-K | $22.50 $21.95 | ▼ −2.48% | ▼ −4.54% | $21.95 (−2.48%) |
Apr 14, 2026 27w ago | 8-K | $22.50 $21.95 | ▼ −2.48% | ▼ −11.00% | $21.95 (−2.48%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers